ePrints

Thyroglobulin in differentiated thyroid cancer

Lookup NU author(s): Dr Petros Perros

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Identification of differentiated thyroid cancer (DTC) is becoming increasingly common. Patients usually have an excellent prognosis. Most undergo total thyroidectomy, radioiodine ablation and treatment with suppressive doses of levothyroxine. Patients require long term follow-up which includes measurement of serum thyroglobulin (Tg). Interpretation of serum Tg requires knowledge of the concurrent thyroid stimulating hormone (TSH) concentration, as secretion is TSH dependant, and an awareness of the limitations of the methods used to measure it. These limitations include the heterogeneity of Tg in serum, the ability of assays to recognise forms of Tg secreted by a tumour, assay biases and not least the potential for interference in immunoassays for Tg from endogenous thyroglobulin antibodies (TgAbs) in patient serum. This review considers what the clinician wants to know and how Tg results can be interpreted in light of an awareness of assay limitations. (C) 2014 Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Evans C, Tennant S, Perros P

Publication type: Review

Publication status: Published

Journal: Clinica Chimica Acta

Year: 2015

Volume: 444

Pages: 310-317

Print publication date: 15/04/2015

Online publication date: 29/10/2014

Acceptance date: 24/10/2014

ISSN (print): 0009-8981

ISSN (electronic): 1873-3492

Publisher: ELSEVIER SCIENCE BV

URL: http://dx.doi.org/10.1016/j.cca.2014.10.035

DOI: 10.1016/j.cca.2014.10.035

Share